Colleen Delaney (left) explaining the process Nohla uses to grow and control stem cells to Governor Jay Inslee. (GeekWire Photo / Clare McGrane)
Just days after announcing $45 million in new funding, startup Nohla Therapeutics has released extended results from a study of dilanubicel — its flagship leukemia treatment that works alongside stem cell transplants using donated umbilical cord blood.
Five years after their transplants, 86 percent of patients (13 out of 15) in the study have survived the disease and are still cancer free. None of the patients experienced severe graft versus host disease, a major concern for stem cell transplant recipients.
The results show a higher survival rate than the average for leukemia patients, although those rates vary greatly depending on the patients’ age and the kind of leukemia they have.
It’s good news for Nohla, which is developing a variety of cancer treatments that augment cord blood transplants and make them more effective.
“These results demonstrate that infusion of dilanubicel given with a cord blood transplant was safe and led to faster neutrophil and platelet recovery, but more importantly showed excellent long-term survival with no transplant-related mortality or severe (grade 3-4) acute graft vs. host disease,” Nohla Co-founder and Chief Medical Officer Colleen Delaney said in a press release.
“We expect to have top-line results later this year from Nohla’s ongoing randomized Phase 2b trial coordinated by the Fred Hutch evaluating dilanubicel in 160 patients with hematologic malignancies receiving a cord blood transplant,” she said.
Nohla Therapeutics Co-founder and Chief Medical Officer Colleen Delaney (left) and CEO Kathleen Fanning. (GeekWire Photo / Clare McGrane)
The study followed 15 patients who ranged in age from just 5 years old to 45. They had a variety of leukemia sub-types: Eight had acute lymphoblastic leukemia, six had acute myeloid leukemia and one had …read more